Abstract:
PURPOSE: A composition containing biochanin A or pharmaceutically acceptable salt thereof for treating angiogenesis-associated diseases is provided to treat various diseases. CONSTITUTION: A composition for treating angiogenesis-associated diseases contains biochanin A or pharmaceutically acceptable salt thereof as an active ingredient. The angiogenesis-associated diseases are cancer, diabetetic retinopathy, rheumatic arthritis, psoriasis, inflammation, endometriosis, aging or hemandioma. A pharmaceutical composition for suppressing angiogenesis contains biochanin A or pharmaceutically acceptable salt thereof as an active ingredient.
Abstract:
PURPOSE: A composition containign sesamol or pharmaceutically acceptable salt is provided to suppress angiogenesis and to treat cancer, diabetic retinopathy, rheumatic arthritis, and psoriasis. CONSTITUTION: A composition for treating angiogenesis-associated diseases contains sesemol or pharmaceutically acceptable salt thereof as an active ingredient. The angiogenesis-associated diseases are cancer, diabetic retinopaghy, rheumatic arthritis, psoriasis, inflammation, endometriosis, and hemandioma. The sesamol or pharmaceutically acceptable salt thereof is contained in 0.1-10 wt%.
Abstract:
PURPOSE: A composition containing poly gamma glutamic acid for preventing and treating obesity is provided to suppress differentiation of adipocytes and to activate AMPK(5'AMP-activated protein kinase). CONSTITUTION: A composition for preventing and treating obesity contains poly gamma glutamic acid(PGA) as an active ingredient. The molecular weight of PGA is 100kDa to 15,000kDa. The composition is a pharmaceutical composition or food additive. The composition further contains pharmacologically acceptable carrier. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, external use, suppository, or sterilized injection solution.
Abstract:
본 발명은 S-아릴 시스테인을 유효성분으로 함유하는 비만으로 유도된 염증 치료용 조성물에 관한 것으로 본 발명에 의한 조성물은 아디포넥틴의 발현을 유도하고 비만 매개 염증 반응에 관여하는 IL-6 및 MCP-1의 발현을 감소시켜 비만으로 유도된 염증을 예방 및 치료할 수 있다.
Abstract:
The present invention relates to a composition for treating obesity-induced inflammation, wherein the composition contains myristicin as an active ingredient. The composition of the present invention induces the expression of adiponectin and decreases the expression of IL-6 and MCP-1 which are involved in obesity-mediated inflammation reaction so that obesity-induced inflammation can be prevented and treated.
Abstract:
본 발명은 어랩틴(Auraptene)을 유효성분으로 함유하는 신생혈관 촉진용 약학조성물에 관한 것으로, 본 발명에 의한 신생혈관 촉진용 약학조성물은 유효성분인 어랩틴에 의해 혈관 신생을 촉진시켜 피부판 재생, 상처 및 화상치유, 인공피부이식 및 이식용 혈관 제조 등의 조직 재생에 효과적이다.